{"count": 14, "results": [{"_id": "34052331", "pmid": 34052331, "title": "Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding.", "journal": "Cancer Lett", "authors": ["Alsheikh HAM", "Metge BJ", "Ha CM", "Hinshaw DC", "Mota MSV", "Kammerud SC", "Lama-Sherpa T", "Sharafeldin N", "Wende AR", "Samant RS", "Shevde LA"], "date": "2021-10-01T00:00:00Z", "doi": "10.1016/j.canlet.2021.05.022", "meta_date_publication": "2021 Oct 1", "meta_volume": "517", "meta_issue": "", "meta_pages": "24-34", "score": 50259.41, "text_hl": "These @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@tumors@@@ also presented with a distinct stromal profile characterized by altered collagen architecture, increased infiltration by @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@tumor@@@-permissive M2 macrophages, and early metastatic seeding compared to non-@DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@/lean @SPECIES_10090 @@@mice@@@. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ treatment of the @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@/@DISEASE_Obesity @DISEASE_MESH:D009765 @@@obese@@@ @SPECIES_10090 @@@mice@@@ effectively normalized @CHEMICAL_Glucose @CHEMICAL_MESH:D005947 @@@glucose@@@ levels, reconfigured the @<m>DISEASE_Mammary_Neoplasms_Animal</m> @DISEASE_MESH:D015674 @@@mammary tumor@@@ milieu, and decreased metastatic seeding. ", "citations": {"NLM": "Alsheikh HAM, Metge BJ, Ha CM, Hinshaw DC, Mota MSV, Kammerud SC, Lama-Sherpa T, Sharafeldin N, Wende AR, Samant RS, Shevde LA. Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding. Cancer Lett. 2021 Oct 1;517():24-34. PMID: 34052331", "BibTeX": "@article{34052331, title={Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding.}, author={Alsheikh HAM and Metge BJ and Ha CM and Hinshaw DC and Mota MSV and Kammerud SC and Lama-Sherpa T and Sharafeldin N and Wende AR and Samant RS and Shevde LA}, journal={Cancer Lett}, volume={517}, pages={24-34}}"}}, {"_id": "34733370", "pmid": 34733370, "pmcid": "PMC8561621", "title": "Metformin inhibits the proliferation of canine mammary gland tumor cells through the AMPK/AKT/mTOR signaling pathway in vitro", "journal": "Oncol Lett", "authors": ["Fan Y", "Ren X", "Wang Y", "Xu E", "Wang S", "Ge R", "Liu Y"], "date": "2021-12-01T00:00:00Z", "doi": "10.3892/ol.2021.13113", "meta_date_publication": "2021 Dec", "meta_volume": "22", "meta_issue": "6", "meta_pages": "852", "score": 50258.562, "text_hl": "...Effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on the @SPECIES_9615 @@@canine@@@ @<m>DISEASE_Mammary_Neoplasms_Animal</m> @DISEASE_MESH:D015674 @@@mammary gland tumor@@@ cell cycle. ", "citations": {"NLM": "Fan Y, Ren X, Wang Y, Xu E, Wang S, Ge R, Liu Y. Metformin inhibits the proliferation of canine mammary gland tumor cells through the AMPK/AKT/mTOR signaling pathway in vitro Oncol Lett. 2021 Dec;22(6):852. PMID: 34733370", "BibTeX": "@article{34733370, title={Metformin inhibits the proliferation of canine mammary gland tumor cells through the AMPK/AKT/mTOR signaling pathway in vitro}, author={Fan Y and Ren X and Wang Y and Xu E and Wang S and Ge R and Liu Y}, journal={Oncol Lett}, volume={22}, number={6}, pages={852}}"}}, {"_id": "32994182", "pmid": 32994182, "title": "Metformin Mitigates DPP-4 Inhibitor-Induced Breast Cancer Metastasis via Suppression of mTOR Signaling.", "journal": "Mol Cancer Res", "authors": ["Kawakita E", "Yang F", "Kumagai A", "Takagaki Y", "Kitada M", "Yoshitomi Y", "Ikeda T", "Nakamura Y", "Ishigaki Y", "Kanasaki K", "Koya D"], "date": "2021-01-01T00:00:00Z", "doi": "10.1158/1541-7786.MCR-20-0115", "meta_date_publication": "2021 Jan", "meta_volume": "19", "meta_issue": "1", "meta_pages": "61-73", "score": 50244.523, "text_hl": "We also analyzed @SPECIES_10090 @@@mice@@@ transplanted with shRNA-mediated @GENE_DPP4 @GENE_13482 @@@DPP-4@@@ knockdown @CELLLINE_CVCL:0125 @@@4T1@@@ cells. Treatment with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ inhibited the @DISEASE_Neoplasm_Metastasis @DISEASE_MESH:D009362 @@@lung metastasis@@@ of @GENE_DPP4 @GENE_13482 @@@DPP-4@@@-deficient @CELLLINE_CVCL:0125 @@@4T1@@@ @<m>DISEASE_Mammary_Neoplasms_Animal</m> @DISEASE_MESH:D015674 @@@mammary tumor@@@ cells generated by either @CHEMICAL_KR_62436 @CHEMICAL_MESH:C503941 @@@KR@@@ administration or @GENE_DPP4 @GENE_13482 @@@DPP-4@@@ knockdown. ", "citations": {"NLM": "Kawakita E, Yang F, Kumagai A, Takagaki Y, Kitada M, Yoshitomi Y, Ikeda T, Nakamura Y, Ishigaki Y, Kanasaki K, Koya D. Metformin Mitigates DPP-4 Inhibitor-Induced Breast Cancer Metastasis via Suppression of mTOR Signaling. Mol Cancer Res. 2021 Jan;19(1):61-73. PMID: 32994182", "BibTeX": "@article{32994182, title={Metformin Mitigates DPP-4 Inhibitor-Induced Breast Cancer Metastasis via Suppression of mTOR Signaling.}, author={Kawakita E and Yang F and Kumagai A and Takagaki Y and Kitada M and Yoshitomi Y and Ikeda T and Nakamura Y and Ishigaki Y and Kanasaki K and Koya D}, journal={Mol Cancer Res}, volume={19}, number={1}, pages={61-73}}"}}, {"_id": "39651199", "pmid": 39651199, "title": "Targeting the menopause transition with metformin improves breast cancer outcomes, but discontinuation has deleterious effects on metabolic health: Findings from a preclinical model of postmenopausal breast cancer.", "journal": "bioRxiv", "authors": ["Corleto KA", "Schedin P", "Kotta AS", "Strandmo JL", "Foster SM", "Lammoglia N", "Karmakar M", "Carroll RJ", "MacLean PS", "Giles ED"], "date": "2024-11-26T00:00:00Z", "doi": "10.1101/2024.11.25.625083", "meta_date_publication": "2024 Nov 26", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50244.113, "text_hl": "In a @SPECIES_10116 @@@rat@@@ model of high-fat-diet and menopause-induced @DISEASE_Weight_Gain @DISEASE_MESH:D015430 @@@weight gain@@@, we previously reported that treatment with the anti-@DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ drug @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ for 8-weeks after ovariectomy (OVX; modeling menopause) reduced growth of existing @<m>DISEASE_Mammary_Neoplasms_Animal</m> @DISEASE_MESH:D015674 @@@mammary tumors@@@ and inhibited new @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@tumor@@@ formation. ", "citations": {"NLM": "Corleto KA, Schedin P, Kotta AS, Strandmo JL, Foster SM, Lammoglia N, Karmakar M, Carroll RJ, MacLean PS, Giles ED. Targeting the menopause transition with metformin improves breast cancer outcomes, but discontinuation has deleterious effects on metabolic health: Findings from a preclinical model of postmenopausal breast cancer. bioRxiv. 2024 Nov 26;():. PMID: 39651199", "BibTeX": "@article{39651199, title={Targeting the menopause transition with metformin improves breast cancer outcomes, but discontinuation has deleterious effects on metabolic health: Findings from a preclinical model of postmenopausal breast cancer.}, author={Corleto KA and Schedin P and Kotta AS and Strandmo JL and Foster SM and Lammoglia N and Karmakar M and Carroll RJ and MacLean PS and Giles ED}, journal={bioRxiv}}"}}, {"_id": "32905620", "pmid": 32905620, "title": "Metformin potentiates the chemotherapeutic effects of doxorubicin on 2-amino-1-methyl-6-phenylimidazo[4,5b] pyridine-induced Mammary Carcinoma in rats.", "journal": "Fundam Clin Pharmacol", "authors": ["Salim E", "El-Sisi AE", "Sokar S", "El-Sayad M", "Moussa E"], "date": "2021-08-01T00:00:00Z", "doi": "10.1111/fcp.12604", "meta_date_publication": "2021 Aug", "meta_volume": "35", "meta_issue": "4", "meta_pages": "700-713", "score": 50242.1, "text_hl": "Moreover, the quantitative mRNA expression of @GENE_ESR1 @GENE_24890 @@@ERalpha@@@ was significantly decreased in @<m>DISEASE_Mammary_Neoplasms_Animal</m> @DISEASE_MESH:D015674 @@@mammary tumors@@@ from @CHEMICAL_2_amino_1_methyl_6_phenylimidazo(4_5_b)pyridine @CHEMICAL_MESH:C049584 @@@PhIP@@@ + @CHEMICAL_Doxorubicin @CHEMICAL_MESH:D004317 @@@Dox@@@+@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Met@@@ combined group more than the @CHEMICAL_2_amino_1_methyl_6_phenylimidazo(4_5_b)pyridine @CHEMICAL_MESH:C049584 @@@PhIP@@@ + @CHEMICAL_Doxorubicin @CHEMICAL_MESH:D004317 @@@Dox@@@ group. ", "citations": {"NLM": "Salim E, El-Sisi AE, Sokar S, El-Sayad M, Moussa E. Metformin potentiates the chemotherapeutic effects of doxorubicin on 2-amino-1-methyl-6-phenylimidazo[4,5b] pyridine-induced Mammary Carcinoma in rats. Fundam Clin Pharmacol. 2021 Aug;35(4):700-713. PMID: 32905620", "BibTeX": "@article{32905620, title={Metformin potentiates the chemotherapeutic effects of doxorubicin on 2-amino-1-methyl-6-phenylimidazo[4,5b] pyridine-induced Mammary Carcinoma in rats.}, author={Salim E and El-Sisi AE and Sokar S and El-Sayad M and Moussa E}, journal={Fundam Clin Pharmacol}, volume={35}, number={4}, pages={700-713}}"}}, {"_id": "30569877", "pmid": 30569877, "title": "Evaluation of Angiogenesis Process after Metformin and LY294002 Treatment in Mammary Tumor.", "journal": "Anticancer Agents Med Chem", "authors": ["Moschetta MG", "Leonel C", "Maschio-Signorini LB", "Borin TF", "Gelaleti GB", "Jardim-Perassi BV", "Ferreira LC", "Sonehara NM", "Carvalho LGS", "Hellmén E", "de Campos Zuccari DAP"], "date": "2019-01-01T00:00:00Z", "doi": "10.2174/1871520619666181218164050", "meta_date_publication": "2019", "meta_volume": "19", "meta_issue": "5", "meta_pages": "655-666", "score": 50067.934, "text_hl": "Evaluation of Angiogenesis Process after @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and @CHEMICAL_2_(4_morpholinyl)_8_phenyl_4H_1_benzopyran_4_one @CHEMICAL_MESH:C085911 @@@LY294002@@@ Treatment in @<m>DISEASE_Mammary_Neoplasms_Animal</m> @DISEASE_MESH:D015674 @@@Mammary Tumor@@@.", "citations": {"NLM": "Moschetta MG, Leonel C, Maschio-Signorini LB, Borin TF, Gelaleti GB, Jardim-Perassi BV, Ferreira LC, Sonehara NM, Carvalho LGS, Hellmén E, de Campos Zuccari DAP. Evaluation of Angiogenesis Process after Metformin and LY294002 Treatment in Mammary Tumor. Anticancer Agents Med Chem. 2019;19(5):655-666. PMID: 30569877", "BibTeX": "@article{30569877, title={Evaluation of Angiogenesis Process after Metformin and LY294002 Treatment in Mammary Tumor.}, author={Moschetta MG and Leonel C and Maschio-Signorini LB and Borin TF and Gelaleti GB and Jardim-Perassi BV and Ferreira LC and Sonehara NM and Carvalho LGS and Hellmén E and de Campos Zuccari DAP}, journal={Anticancer Agents Med Chem}, volume={19}, number={5}, pages={655-666}}"}}, {"_id": "16224592", "pmid": 16224592, "title": "Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice.", "journal": "Bull Exp Biol Med", "authors": ["Anisimov VN", "Egormin PA", "Bershtein LM", "Zabezhinskii MA", "Piskunova TS", "Popovich IG", "Semenchenko AV"], "date": "2005-06-01T00:00:00Z", "doi": "10.1007/s10517-005-0389-9", "meta_date_publication": "2005 Jun", "meta_volume": "139", "meta_issue": "6", "meta_pages": "721-3", "score": 50065.965, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ decelerates aging and development of @<m>DISEASE_Mammary_Neoplasms_Animal</m> @DISEASE_MESH:D015674 @@@mammary tumors@@@ in @GENE_ERBB2 @GENE_13866 @@@HER-2/neu@@@ transgenic @SPECIES_10090 @@@mice@@@.", "citations": {"NLM": "Anisimov VN, Egormin PA, Bershtein LM, Zabezhinskii MA, Piskunova TS, Popovich IG, Semenchenko AV. Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med. 2005 Jun;139(6):721-3. PMID: 16224592", "BibTeX": "@article{16224592, title={Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice.}, author={Anisimov VN and Egormin PA and Bershtein LM and Zabezhinskii MA and Piskunova TS and Popovich IG and Semenchenko AV}, journal={Bull Exp Biol Med}, volume={139}, number={6}, pages={721-3}}"}}, {"_id": "29898754", "pmid": 29898754, "pmcid": "PMC6000949", "title": "Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer", "journal": "Breast Cancer Res", "authors": ["Giles ED", "Jindal S", "Wellberg EA", "Schedin T", "Anderson SM", "Thor AD", "Edwards DP", "MacLean PS", "Schedin P"], "date": "2018-06-14T00:00:00Z", "doi": "10.1186/s13058-018-0974-2", "meta_date_publication": "2018 Jun 14", "meta_volume": "20", "meta_issue": "1", "meta_pages": "50", "score": 50064.76, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ decreased the size of existing @<m>DISEASE_Mammary_Neoplasms_Animal</m> @DISEASE_MESH:D015674 @@@mammary tumors@@@ and inhibited new @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@tumor@@@ formation without changing body weight or @DISEASE_Neoplasms_Adipose_Tissue @DISEASE_MESH:D018205 @@@adiposity@@@. ", "citations": {"NLM": "Giles ED, Jindal S, Wellberg EA, Schedin T, Anderson SM, Thor AD, Edwards DP, MacLean PS, Schedin P. Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer Breast Cancer Res. 2018 Jun 14;20(1):50. PMID: 29898754", "BibTeX": "@article{29898754, title={Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer}, author={Giles ED and Jindal S and Wellberg EA and Schedin T and Anderson SM and Thor AD and Edwards DP and MacLean PS and Schedin P}, journal={Breast Cancer Res}, volume={20}, number={1}, pages={50}}"}}, {"_id": "28154203", "pmid": 28154203, "title": "Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression In Vivo.", "journal": "Cancer Prev Res (Phila)", "authors": ["Checkley LA", "Rudolph MC", "Wellberg EA", "Giles ED", "Wahdan-Alaswad RS", "Houck JA", "Edgerton SM", "Thor AD", "Schedin P", "Anderson SM", "MacLean PS"], "date": "2017-03-01T00:00:00Z", "doi": "10.1158/1940-6207.CAPR-16-0211-T", "meta_date_publication": "2017 Mar", "meta_volume": "10", "meta_issue": "3", "meta_pages": "198-207", "score": 50063.004, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Accumulation Correlates with @GENE_SLC22A2 @GENE_29503 @@@Organic Cation Transporter 2@@@ Protein Expression and Predicts @<m>DISEASE_Mammary_Neoplasms_Animal</m> @DISEASE_MESH:D015674 @@@Mammary Tumor@@@ Regression In Vivo.", "citations": {"NLM": "Checkley LA, Rudolph MC, Wellberg EA, Giles ED, Wahdan-Alaswad RS, Houck JA, Edgerton SM, Thor AD, Schedin P, Anderson SM, MacLean PS. Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression In Vivo. Cancer Prev Res (Phila). 2017 Mar;10(3):198-207. PMID: 28154203", "BibTeX": "@article{28154203, title={Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression In Vivo.}, author={Checkley LA and Rudolph MC and Wellberg EA and Giles ED and Wahdan-Alaswad RS and Houck JA and Edgerton SM and Thor AD and Schedin P and Anderson SM and MacLean PS}, journal={Cancer Prev Res (Phila)}, volume={10}, number={3}, pages={198-207}}"}}, {"_id": "30924377", "pmid": 30924377, "title": "Anticancer effect of metformin against 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine-induced rat mammary carcinogenesis is through AMPK pathway and modulation of oxidative stress markers.", "journal": "Hum Exp Toxicol", "authors": ["El-Sisi AE", "Sokar SS", "El-Sayad ME", "Moussa EA", "Salim EI"], "date": "2019-06-01T00:00:00Z", "doi": "10.1177/0960327119839192", "meta_date_publication": "2019 Jun", "meta_volume": "38", "meta_issue": "6", "meta_pages": "703-712", "score": 50052.758, "text_hl": "In parallel, @<m>DISEASE_Mammary_Neoplasms_Animal</m> @DISEASE_MESH:D015674 @@@mammary gland tumors@@@ found in @CHEMICAL_2_amino_1_methyl_6_phenylimidazo(4_5_b)pyridine @CHEMICAL_MESH:C049584 @@@PhIP@@@+@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ group were all histologically benign included only (@DISEASE_Hyperplasia @DISEASE_MESH:D006965 @@@hyperplasia@@@). ", "citations": {"NLM": "El-Sisi AE, Sokar SS, El-Sayad ME, Moussa EA, Salim EI. Anticancer effect of metformin against 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine-induced rat mammary carcinogenesis is through AMPK pathway and modulation of oxidative stress markers. Hum Exp Toxicol. 2019 Jun;38(6):703-712. PMID: 30924377", "BibTeX": "@article{30924377, title={Anticancer effect of metformin against 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine-induced rat mammary carcinogenesis is through AMPK pathway and modulation of oxidative stress markers.}, author={El-Sisi AE and Sokar SS and El-Sayad ME and Moussa EA and Salim EI}, journal={Hum Exp Toxicol}, volume={38}, number={6}, pages={703-712}}"}}]}